Fronto-Temporal Lobar Degeneration (FTLD)
Conditions
Interventions
Dosage is 7.5 g/day divided into 2 to 3 oral doses, and taken before or between meals. Dosage may be adjustd according to the patient'
s age, weight and symptoms. Administration period : 8 weeks
Sponsors
Ehime University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patientsw diagnosed with Fronto-Temporal Dementia (FTD) or Semantic Dementia (SD) according to the clinical criteria of Intrenational Working Group(Neary D. et al, 1998) of Fronto-Temporal Lober Degeneration. 2) Patients with NPI-D score of 4 and hugher in 1 or more items at the start f the treatment. 3) Patients with serum potassium levels within the standard range of the facility when measured within 8 weeks before the start of teatment. 4) Medical Consultation : Outpatients as a general ule, but inpatients from hospitals, clinics and medical facilities are also accepted (changes in medical setting where patients receive care during the study, however, is unacceptable). 5) Outpatients must have a reliable caregiver at home during the entire duration of the study who can tranport the patient to the hospital for conculusion. 6)Inpatients must have been receiving care at their respective medical facility for least 2 weeks before the strart of the study, and must also have a caregiver or belong to a nursing home during the entire dution of the study.
Exclusion criteria
Exclusion criteria: 1) Patients with concomitant diagnosis of malignant cancer. 2) Patients with concomitant diagnosis o sevious heart, liver, lung or kidney disease, blood disorders, or other life-threatening diseases. 3) Ptients with other forms of dementia (AD, VD, DLB) besides Fronto-Temporal Degeneration (FTLD) 4) Patients who fail to meet the DSM-IV diagnostic criteria for our study, but show symptoms of BPSD due to other concomitant neurodegerative disease, Scizophrenia, Bipolar disorder, Major depressive disorder or other psychiatric disorders. 5) Patients with delirium due to alcohol or drug addicution, metabolic poisoning, or inflammatory disease. 6) Patients who are unable to take oral medications. 7) Patients who altered their dosage or method of administration of SSRI, 8 weeks before the start of the study. 8) Ptients who took long acting antipsychotic durgs (such as haloperidol decanoate) 4 weeks before the start of treatment. 9) Patients who are determined as unfit for the study by attending physicians for reasons other than those stated above.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NPI-D | — |
Secondary
| Measure | Time frame |
|---|---|
| SRI, Barthel Index, Zaril Caregiver Burden Scale MMSE, swallowing ability, appetite level, questionnaire regarding eating patterns, cerebral blood flow | — |
Countries
Japan
Contacts
Public ContactSatoshi TANIMUKAI
Ehime University Graduate School of Medicine Department of Neuropsychiatry, Neuroscience
Outcome results
None listed